Moreover, oestrogen receptor positive (ER +) cancers have the tendency to metastasise to bone and are associated with favourable outcomes [5], likely due to the presence of steroid hormone receptors providing targets for endocrine agents, from which there is typically the best treatment for establishing disease control, even in the setting of stage IV disease [10–12]. This evidence concerns the gene ESR1 and cancer.